- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Health Bulletin 23/March/2023 - Video
Overview
Here are the top health stories for the day:
New Bond Policy: Gujarat proposes 1.5 years of mandatory service for doctors completing MBBS, PG degree
Formulating a new bond policy for doctors who fail to adhere to their service bonds after completing both MBBS and Postgraduate medial courses, the State Government of Gujarat has proposed to allow such doctors to serve for only one-and-a-half years instead of the mandatory service of two years.
This proposal for the new bond policy was announced by the Health Minister of the State Rushikesh Patel during the Question Hour at the State Assembly on Monday.
For more details, check out the link given below:
Free MBBS education? This upcoming medical college has announced to offer 100 MBBS seats for no fee
Bringing good news to the medical aspirants in Karnataka, the newly set up Sri Madhusudan Sai Institute of Medical Sciences and Research is all prepared to offer 100 MBBS seats free of cost from 2023-2024. As no fees will be collected from all 100 students, they will have to agree to serve for five years in the college hospital after their graduation.
The medical college, which will be inaugurated by Prime Minister Narendra Modi on March 25 has already got the permission from the National Medical Commission (NMC) on March 10, 2023 to admit MBBS students in 100 seats from this academic year.
For more details, check out the link given below:
Free MBBS Education? This Upcoming Medical College Has Announced To Offer 100 MBBS Seats For No Fee
Andhra Pradesh High Court junks plea challenging minimum age criteria for NEET
The Andhra Pradesh High Court division bench recently dismissed a plea challenging the constitutional validity of the minimum age criteria for appearing in the National Eligibility-cum-Entrance Test (NEET).
As per Regulation 4(1) of the Medical Council of India Regulations on Graduate Medical Education, 1997, "No Candidate shall be allowed to be admitted to the Medical Curriculum proper of first Bachelor of Medicine and Bachelor of Surgery (MBBS) Course until: (1) He/she shall complete the age of 17 years on or before 31st December of the year of admission to the MBBS Course."
For more details, check out the link given below:
NEET: AP High Court Junks Plea Challenging Minimum Age Criteria
Novartis not to move ahead with UK trial of anti-cholesterol drug Leqvio
Novartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally planned as part of its partnership with NHS England to investigate the potential of the anti-cholesterol drug Leqvio.
"After careful evaluation, we have decided not to move forward with ORION-17," a spokesperson said in an emailed statement. "We continue to have very high ambitions for Leqvio and are encouraged by the foundation we have built and the traction we have seen so far, both in the UK and around the world."
For more details, check out the link given below:
Novartis Not To Move Ahead With UK Trial Of Anti-Cholesterol Drug Leqvio
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)